Loading clinical trials...

Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study | Clinical Trials | Clareo Health

UNKNOWNNA

Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study

NCT03651674•Xidian University

View on ClinicalTrials.gov

Summary

For more severe and treatment-resistant cases in schizophrenia and bipolar disorder, electroconvulsive therapy (ECT) is often very effective. The purpose of this study is to investigate the brain structure and function changes after ECT treatment. The neuroimaging marker which may predict the outcome of ECT is also studied in this research.

Eligibility

Age

15 - 70 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•International classification of diseases (ICD) diagnosis of Schizophrenia and bipolar disorder;
•Ages 15-70
•All participants are ethnic Han
•Not received ECT treatment before
•PANSS ≥ 60 for schizophrenia subjects
•The patient's written informed consent can be obtained. If the patient is incapacitated during the onset period, the written informed consent of the legal guardian is required.

Exclusion Criteria

•Those with mental retardation, generalized developmental disorders,delirium, dementia, memory impairment or cognitive impairment that meet the diagnostic criteria of ICD-10;
•Patients with cognitive impairment, such as Parkinson's, multiple sclerosis, stroke, and patients who meet the diagnostic criteria for ICD-10 alcohol dependence (except nicotine dependence);
•The course of the disease is very short (fast phase inversion), such as 4 or more different mood abnormalities (depression, mild mania, mania, mental illness) in one year;
•With severe unstable physical diseases; diagnosed diabetes, thyroid disease, hypertension, heart disease, etc.;
•Narrow angle glaucoma;
•With a history of epilepsy, except those with febrile seizures;
•Have or have had drug-induced malignant syndrome and severe tardive dyskinesia;
•With serious suicide attempts;
•Cannot take medication as directed by their doctors, or who do not have guardians;
•Pregnant or lactating women, or those who plan to become pregnant;

Key Dates

Start Date

September 20, 2018

Primary Completion Date

December 31, 2019

Completion Date

April 1, 2020

Last Updated

August 29, 2018

Enrollment

200

ESTIMATED participants

Conditions

Schizophrenia, Bipolar Disorder

Interventions

ECT treatment

DEVICE

Drug treatment

DRUG

Contacts

Wei Qin

CONTACT

86-02981891070 wqin@xidian.edu.cn